ClinicalTrials.gg
Status unknownNCT02979132Updated Oct 9, 2018

Iron Long-Term Labelling Study Switzerland

An interventional study of Eisensulfat LOMAPHARM 50 mg and Ferinject(R) in Iron Absorption, sponsored by Prof. Michael B. Zimmermann. Status unknown at 1 site in Switzerland. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by Prof. Michael B. Zimmermann · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Conventional indirect indicators of iron status, using serum and red blood cell biomarkers, are confounded by inflammation from common infections and are therefore of limited use in populations carrying a high burden of infection and inflammation, as for example women of reproductive age in malaria endemic areas in developing countries. Even without the confounding effect of inflammation, current markers of iron status are insensitive to small changes in dietary iron and do not allow to establish associations between dietary, lifestyle and genetic factors and iron balance. With a new method based on the dilution of a previously administered and equilibrated stable isotope signal, an accurate measurement of long-term oral iron balance and absorption is possible, allowing the estimation of iron requirements and potentially providing fundamental guidance for supplementation and fortification programs in both healthy and chronically inflamed/infected patients. In the current study the novel methodology will be validated in generally healthy subjects with low iron status. The technique will be used to assess dietary and lifestyle determinants of iron status and to compare the effect on iron balance and iron status of three distinct, commonly used iron interventions: food fortification with iron; oral iron supplementation, and intravenous iron infusion.

02

Conditions studied

  • Iron Absorption
03

In context

Lead sponsor

Prof. Michael B. Zimmermann is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have participated in a former absorption study in our lab,
  • Signed written to participate in the new study,
  • Serum ferritin \< 25 µg/L

Exclusion criteria

Exclusion Criteria:

  • Anaemia ( \< 117 g/L),
  • Any metabolic, gastrointestinal, kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement),
  • Allergic or similar reactions against iron supplements,
  • Known fructose intolerance, glucose-galactose malabsorption or saccharase-isomaltase deficiency,
  • Known to ponceau R4 and ponceau R4 aluminium salt (E124)
  • Continuous/long-term use of medication during the whole study (except for ),
  • Regular consumption of mineral and vitamin supplements within 2 weeks prior to 1st supplement administration (more than 3 consecutive days or more than 5 times within 14 days),
  • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 6 months,
  • pregnancy or breast feeding,
  • Intention to become pregnant during the course of the study,
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Participation in another study with drug within the 30 days preceding and during the present study,
  • Enrollment of the investigator, his/her family members, employees and other dependent persons
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Oral Iron Supplementation

    Eisensulfat LOMAPHARM 50 mg administration for 90 days

    Drug: Eisensulfat LOMAPHARM 50 mg

  • Active comparator
    Intravenous Iron Supplementation

    Single-dose Ferinject(R) administration

    Drug: Ferinject(R)

  • Active comparator
    Food Fortification with Iron

    Consumption of iron-fortified biscuits (15 mg Fe in form of FeSO4) for 90 d

    Dietary Supplement: iron fortified biscuits

Interventions

  • DrugEisensulfat LOMAPHARM 50 mg

    oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days

    Also known as: Eisentabletten

  • Single-dose Ferinject(R) administration

    Also known as: Iron Infusion

  • Dietary supplementiron fortified biscuits

    consumption of an iron-fortfied biscuit every morning for 90 days

    Also known as: HUG-Biskuits

06

What researchers measure

Primary outcomes

  1. iron isotope composition in blood

    tracer to tracee rate in venous blood samples at different time points

    Time frame: 9 months

07

Study locations

1 site
  • Human Nutrition Laboratory, ETH Zürich
    Zürich, Zurich 8092, Switzerland
08

References and documents

Publications

  • Speich C, Mitchikpe CES, Cercamondi CI, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Direct assessment of body iron balance in women with and without iron supplementation using a long-term isotope dilution method in Benin and Switzerland. Am J Clin Nutr. 2021 Jun 1;113(6):1657-1669. doi: 10.1093/ajcn/nqaa433. PubMed 33693464 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02979132
Lead sponsor
Prof. Michael B. Zimmermann
Responsible party
Prof. Michael B. Zimmermann (Professor, Swiss Federal Institute of Technology) — Sponsor-investigator
First posted
Dec 1, 2016
Start date
Sep 1, 2017
Primary completion
Jul 31, 2018
Completion
Mar 31, 2019 (estimated)
Last update
Oct 9, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion